[go: up one dir, main page]

DE69730352D1 - Verfahren zur herstellung eines arzneimittelkomplexes - Google Patents

Verfahren zur herstellung eines arzneimittelkomplexes

Info

Publication number
DE69730352D1
DE69730352D1 DE69730352T DE69730352T DE69730352D1 DE 69730352 D1 DE69730352 D1 DE 69730352D1 DE 69730352 T DE69730352 T DE 69730352T DE 69730352 T DE69730352 T DE 69730352T DE 69730352 D1 DE69730352 D1 DE 69730352D1
Authority
DE
Germany
Prior art keywords
spacer
drug compound
bound
carboxyl groups
polysaccharide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730352T
Other languages
English (en)
Other versions
DE69730352T2 (de
Inventor
Kazuhiro Inoue
Hiroshi Susaki
Masahiro Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of DE69730352D1 publication Critical patent/DE69730352D1/de
Application granted granted Critical
Publication of DE69730352T2 publication Critical patent/DE69730352T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69730352T 1996-06-06 1997-06-05 Verfahren zur herstellung eines arzneimittelkomplexes Expired - Lifetime DE69730352T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14452296 1996-06-06
JP14452296 1996-06-06
PCT/JP1997/001915 WO1997046261A1 (en) 1996-06-06 1997-06-05 Process for producing drug complexes

Publications (2)

Publication Number Publication Date
DE69730352D1 true DE69730352D1 (de) 2004-09-23
DE69730352T2 DE69730352T2 (de) 2005-09-08

Family

ID=15364300

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730352T Expired - Lifetime DE69730352T2 (de) 1996-06-06 1997-06-05 Verfahren zur herstellung eines arzneimittelkomplexes

Country Status (16)

Country Link
US (1) US6291671B1 (de)
EP (1) EP0955064B1 (de)
JP (1) JP4137184B2 (de)
CN (1) CN1227034C (de)
AT (1) ATE273716T1 (de)
AU (1) AU723442B2 (de)
CA (1) CA2257233A1 (de)
DE (1) DE69730352T2 (de)
DK (1) DK0955064T3 (de)
EA (1) EA001897B1 (de)
ES (1) ES2229355T3 (de)
ID (1) ID17243A (de)
NO (1) NO323626B1 (de)
PT (1) PT955064E (de)
TW (1) TW409058B (de)
WO (1) WO1997046261A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CA2333321A1 (en) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Drug complex
CA2412582A1 (en) * 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Dds compound and process for the preparation thereof
EP1401875A4 (de) * 2001-05-04 2005-01-26 Univ Utah Res Found Hyaluronsäure enthaltende biokonjugate: gezielte abgabe von antikrebsmitteln an krebszellen
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
BRPI0611535B1 (pt) 2005-05-05 2021-11-30 Sensient Flavors Inc Método para processar células de levedura para produzir beta-glucanos e mananas
US8354392B2 (en) 2005-07-06 2013-01-15 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
SMT202000138T1 (it) 2012-10-11 2020-05-08 Daiichi Sankyo Co Ltd Raccordi per coniugati anticorpo-farmaco
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EA033912B1 (ru) 2013-04-10 2019-12-09 Синдевркс, Инк. ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN111228510B (zh) 2013-12-25 2024-06-18 第一三共株式会社 抗trop2抗体-药物偶联物
EP4464707A2 (de) 2014-01-31 2024-11-20 Daiichi Sankyo Company, Limited Anti-her2-antikörper-wirkstoff-konjugat
RS61711B1 (sr) 2014-04-10 2021-05-31 Daiichi Sankyo Co Ltd Anti-her3 antitelo-lek konjugat
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CA3005450A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
TWI862473B (zh) 2016-12-12 2024-11-21 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
IL268102B2 (en) 2017-01-17 2024-12-01 Daiichi Sankyo Co Ltd Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate
TWI855528B (zh) 2017-05-15 2024-09-11 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
PL3794042T3 (pl) 2018-05-18 2024-06-10 Daiichi Sankyo Co., Ltd. Koniugat przeciwciało-lek przeciwciało skierowane przeciwko muc1 - eksatekan
TW202415410A (zh) 2018-07-31 2024-04-16 日商第一三共股份有限公司 抗體-藥物結合物之用途
CN113453721A (zh) 2018-10-26 2021-09-28 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CN114341162A (zh) 2019-07-10 2022-04-12 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746920A (en) * 1980-09-03 1982-03-17 Kyosei Seiyaku Kk Drug for digestive tract
GB2093697A (en) 1980-09-03 1982-09-08 Kyosei Pharmaceutical Co Ltd Agent for alimentary canal
JPS59220197A (ja) * 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2081025A1 (en) 1991-02-21 1992-08-22 Kazuhiro Inoue Carboxymethylmannoglucans and derivatives thereof
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
CA2134348C (en) 1993-02-26 2007-01-02 Hideo Nogusa Polysaccharide derivatives and drug carriers
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts

Also Published As

Publication number Publication date
EP0955064A1 (de) 1999-11-10
US6291671B1 (en) 2001-09-18
ID17243A (id) 1997-12-11
DK0955064T3 (da) 2004-12-06
NO985667D0 (no) 1998-12-04
JP4137184B2 (ja) 2008-08-20
ATE273716T1 (de) 2004-09-15
CN1227034C (zh) 2005-11-16
EP0955064A4 (de) 2000-12-06
EA199900002A1 (ru) 1999-08-26
WO1997046261A1 (en) 1997-12-11
AU723442B2 (en) 2000-08-24
EP0955064B1 (de) 2004-08-18
CA2257233A1 (en) 1997-12-11
CN1227500A (zh) 1999-09-01
NO985667L (no) 1999-02-04
AU2978897A (en) 1998-01-05
DE69730352T2 (de) 2005-09-08
NO323626B1 (no) 2007-06-18
TW409058B (en) 2000-10-21
EA001897B1 (ru) 2001-10-22
PT955064E (pt) 2004-10-29
ES2229355T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
ATE273716T1 (de) Verfahren zur herstellung eines arzneimittelkomplexes
DE69530242D1 (de) Verfahren zur Herstellung von Glutaminsäure durch Fermentation
AU6614594A (en) Method of producing sustained-release preparation
ATE121414T1 (de) Verfahren zur herstellung von erythromcin a-oxim oder eines salzes davon.
CA2399187A1 (en) Kahalalide compounds
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
ATE359256T1 (de) Verfahren zur herstellung von (2r)-2- propyloktansäure
ATA342186A (de) Verfahren zur herstellung eines organischen carbonsaeureanhydrids
ATE264290T1 (de) Verfahren zur herstellung von 5-hydroxy-3-oxo- pentansäure-derivaten
EP1336603A4 (de) Verfahren zur einführung von aminogruppen und verfahren zur synthese von aminosäuren
DE68923534D1 (de) Verfahren zur Herstellung eines organischen Kristalls.
DE69319428D1 (de) Verfahren zur herstellung von vancomycin
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
ATE189220T1 (de) Verfahren zur herstellung von 7-(3-amino- sowie 3-aminomethyl-1-pyrrolidinyl)-3-chinolon- carbonsäuren sowie -naphthyridoncarbonsäuren
RU93004665A (ru) Микробиологический способ гидроксилирования азот-гетероциклических-карбоновых кислот
DE68925951D1 (de) Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze
DE3765370D1 (de) Verfahren zur herstellung eines o-naphtochinondiazidsulfonsaeureesters.
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
ATE128456T1 (de) Verfahren zur herstellung eines alpha-amino- alkohols.
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
ATE222887T1 (de) Verfahren zur herstellung von inorganischen salzen von optisch aktiven phenylglycin-derivaten
EP0226132A3 (de) Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
DE58905083D1 (de) Verfahren zur herstellung von thiophenderivaten sowie dihydrothiophen-1-oxide.
DE69705275D1 (de) Verfahren zur herstellung von n omega-trifluoracetylierten basischen aminosäuren
DE3778380D1 (de) Verfahren zur herstellung organischer hydroxamsaeureester.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition